Targeting the cause of Huntington’s disease
Advancing a non-viral, precision approach to gene editing
We are Incisive Genetics
A gene editing company on a mission to cure Huntington’s disease. Founded by pioneers in allele-selective editing and Huntington’s disease research, we have developed a breakthrough therapeutic approach that targets the genetic cause of disease with precision, and control.
A known cause, but no cure
Huntington’s disease is genetically inevitable. If you inherit the mutation, you will develop the disease – a devastating neurological disorder that robs people of their movement, cognition, and independence. A single genetic mutation in the HTT gene triggers toxic protein production leading to progressive neurodegeneration and loss of normal function.
Despite the gene’s discovery in 1993, no therapy has successfully targeted the mutation itself; leaving tens of thousands of patients without hope for a cure.
A new path to curing Huntington’s disease
Our lead program IG-HD01 combines allele-selective gene editing with our proprietary non-viral delivery platform to target all known pathogenic mechanisms of Huntington’s disease.
Unlike single-shot viral approaches, our LNP-based system allows for adjustable, repeatable dosing to directly and safely target the brain regions most affected by Huntington’s disease.
The result: unprecedented control, safety, and the potential to eliminate the cause of disease.
Learn about our Science
Beyond Huntington’s Disease
Our proprietary LNP/RNP delivery platform transforms the field of genetic medicine and enables additional programs. We are open to partnerships that accelerate patient impact.
